Arcellx, Inc. (ACLX) Stock
ACLX has an Alpha Score of 13 out of 100 (poor), computed on Nov 10, 2026 from 1 of 4 sub-scores.
What is ACLX's Alpha Score?
How it works →Alpha Score of 13 reflects poor overall profile with poor quality. Based on 1 of 4 signals – score is capped at 50 until remaining data ingests.
Computed from 1 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 10, 2026
A rules-based research rating, not a recommendation to buy or sell.
What are ACLX's key statistics?
Key statistics as of Nov 10, 2026
How does ACLX's valuation compare with the Healthcare sector?
| Metric | ACLX | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -1028.05% | 3.60% | 175 |
| Return on equity | -55.46% | 2.93% | 201 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 11, 2026). P/E excludes loss-making companies.
ACLX price chart
Powered by TradingViewWhat does Arcellx, Inc. do?
Arcellx, Inc. is a clinical-stage biotechnology company developing innovative cell therapies for patients with cancer and other incurable diseases. Its lead product candidate, anitocabtagene autoleucel (anito-cel), utilizes the proprietary ddCAR platform and is in phase 3 clinical trials for relapsed or refractory multiple myeloma, featuring D-Domain technology for enhanced control and safety. The company advances ACLX-001, targeting BCMA in phase 1 for the same indication via the ARC-SparX platform, and ACLX-002 in phase 1 against CD123 for relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. Preclinical efforts include ACLX-003 for AML and MDS, alongside programs for solid tumors. Arcellx maintains a strategic collaboration with Kite Pharma, a Gilead company, to co-develop and co-commercialize anito-cel. Founded in 2014 and headquartered in Redwood City, California, Arcellx focuses on engineering safer, more effective, and accessible immunotherapies to transform cancer treatment.